We next explored the relationship between HYAL2 expression and glioma patient survival time, and Kaplan‒Meier survival analysis demonstrated that glioma patients with high HYAL2 expression had a shorter survival time in the TCGA and CGGA datasets (mRNA-array_301, mRNAseq_325 and mRNAseq_693) (Fig. 2F). The gene discussed is HYAL2; the disease is central nervous system cancer.